Skip to main content

Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies : novel affinity ligands and biomimetic membranes

Objetivo

In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any contaminant has to be discarded with the most drastic measures. Such « negative » approach comes at the expense of the recovery of product : yields are poor, thereby inducing a high product cost. Processes are also complex, since they rely on multiple eliminations rather than on recovery of the unique product of interest. Technically, this is mostly due to the lack of specific capture systems that would allow direct, « positive » separation of the vaccine from its environment.Vaccines know no borders. For developing countries, the pressure on costs is even more acute, and local production is a way to try to reach the 1$ per dose target. In this context, water sustainability is a major issue, as it is a most sensitive ingredient in bioproduction.
DiViNe will tackle theses cost and environmental issues with technological answers. The partners will combine two major Nano/biotechnology innovations to develop an integrated purification platform amenable to the different natures of vaccines : glycoconjugates, protein antigens and enveloped viruses. They will implement Nanofitins (novel affinity capture ligands) and Aquaporin-based membranes (energy-saving nano-biomimetics used in the cleantech industry), for a « positive » purification approach. High yields are expected (data from antibody purification with Nanofitins), at affordable cost of goods and with a sustainable approach of water recycling.
Novartis Vaccines brings to the Consortium a broad range of targets, and identical strategies can be applied for biopharmaceuticals in general. The development custom affinity capture processes as a sustainable platform is therefore economically relevant, in a very large market. Beyond the technical partnership, the project is a first run for the partners to structure the platform as a commercial offer for downstream processing of biologics.

Convocatoria de propuestas

H2020-LEIT-BIO-2014-1
Consulte otros proyectos de esta convocatoria

Régimen de financiación

IA - Innovation action

Coordinador

INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Dirección
Avenida Da Republica Quinta Do Marques
2781-901 Oeiras
Portugal
Tipo de actividad
Research Organisations
Aportación de la UE
€ 1 663 706,25

Participantes (5)

AFFILOGIC
Francia
Aportación de la UE
€ 1 146 225
Dirección
Bio Ouest 21 Rue La Noue Bras De Fer
44200 Nantes
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AQUAPORIN AS
Dinamarca
Aportación de la UE
€ 519 400
Dirección
Nymollevej 78
2800 Kobenhavn
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN
Alemania
Aportación de la UE
€ 1 397 000
Dirección
Frankfurter Strasse 250
64293 Darmstadt
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GENIBET - BIOPHARMACEUTICALS SA
Portugal
Aportación de la UE
€ 250 250
Dirección
Avenida Da Republica Quinta Do
2781 901 Oeiras
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GlaxoSmithKline Vaccines Srl
Italia
Aportación de la UE
€ 813 999,25
Dirección
Via Fiorentina
53100 Siena
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)